GNI Group Ltd.

2160.T

2160.TGNI Group Ltd. JP flag

Tokyo

2,157.00

JPY

-52.00

(-2.35%)

21.05EPS

102.47P/E

108.30BMarket Cap

May 19Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

JP3386370005

Return %

Stock

S&P500

-27.88

10.92

60.01

26.22

84.04

120.31

Use logarithmic scale

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	3.33	5.42	5.99	14.06	29.85	38.29	70.39	123.92	176.19	225.01	270.44	366.92	544.7	481.5
Basic EPS, GAAP	-16.07	-16.15	-23.85	-9.4	-18.29	-15.03	-4.66	-4.94	4.3	28.96	22.72	8.19	169.5	137.76
Free Cash Flow per Basic Share	-8.17	-13.37	-28.33	-25.12	-19.43	-15.45	-16.91	-5.53	4.16	23.49	-3.03	-32.58	93.68	49.7
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	3.21	- -	- -	- -
Book Value per Share	-88.98	-90.34	-67.48	-41.71	-58.97	-73.55	46.29	137.4	152.58	176.36	238.49	244.12	457.42	454.87
Tangible Book Value per Share	24.68	20.66	118.44	158.88	138.03	122.12	171.02	81.49	153.43	150.49	257.82	228.22	316.24	305.28
Basic Weighted Avg Shares	27	30	31	34	34	34	38	41	42	43	47	47	48	49
Sales/Revenue/Turnover	90	162	184	475	1,017	1,307	2,648	5,019	7,446	9,774	12,690	17,419	26,011	23,648
Operating Margin (%)	-506.24	-286.87	-427.64	-79.81	-62.28	-21.15	5.82	11.33	17.49	19.13	12.8	7.91	50.4	39.73
Depreciation Expense	98	99	36	33	61	66	90	154	237	330	383	522	608	754
Net Income, GAAP	-435	-482	-731	-317	-623	-513	-175	-200	182	1,258	1,066	389	8,094	6,766
Effective Tax Rate (%)	- -	- -	- -	- -	- -	- -	79.43	47.31	47.4	24.36	95.01	213.07	24.65	34.95
Profit Margin (%)	-482.06	-297.79	-398.03	-66.83	-61.29	-39.26	-6.62	-3.99	2.44	12.87	8.4	2.23	31.12	28.61
Working Capital	744	680	3,188	4,823	3,399	2,921	5,064	4,994	7,025	6,421	15,644	13,644	22,714	19,931
LT Debt	249	261	35	269	469	488	479	1,520	1,157	227	281	158	1,750	1,657
Total Equity	1,162	1,031	3,973	5,798	5,128	4,533	13,482	10,008	13,096	12,769	19,266	19,811	36,053	39,564
Return on Invested Capital (%)	- -	- -	- -	- -	- -	- -	0.31	2.19	4.94	9.42	0.46	-7.34	31.13	16.46
Return on Capital (%)	- -	- -	- -	- -	- -	- -	-17.41	-6.91	-1.93	11.18	17.65	5.59	39.35	39.82
Return on Common Equity (%)	- -	- -	- -	- -	- -	- -	- -	-5.48	3.03	17.83	11.31	3.41	48.42	38.02

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	68.95%	39.21%	49.32%
Net Income, GAAP	227.45%	460.79%	1,981.71%
Free Cash Flow	69.81%	157.36%	-389.23%
Total Cash Common Dividend	- -	- -	- -
Total Equity	35.85%	32.81%	81.98%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Dr. Ying Luo Ph.D.
Full Time Employees: 843
Sector: Healthcare
Industry: Biotechnology
Address: Nihonbashi-Honcho YS Building Tokyo Japan 103-0023
IPO Date: Aug 31, 2007
Website: gnipharma.com
Similar Companies: Cantabio Pharmaceuticals, Inc. (CTBO)
La Jolla Pharmaceutical Company (LJPC)
Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ)
Better Therapeutics, Inc. (BTTX)
Promore Pharma AB (publ) (PROMO.ST)
Novo Nordisk A/S (NONOF)
Business: GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.

	2011 Y	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	3.33	5.42	5.99	14.06	29.85	38.29	70.39	123.92	176.19	225.01	270.44	366.92	544.7	481.5
Basic EPS, GAAP	-16.07	-16.15	-23.85	-9.4	-18.29	-15.03	-4.66	-4.94	4.3	28.96	22.72	8.19	169.5	137.76
Free Cash Flow per Basic Share	-8.17	-13.37	-28.33	-25.12	-19.43	-15.45	-16.91	-5.53	4.16	23.49	-3.03	-32.58	93.68	49.7
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	3.21	- -	- -	- -
Book Value per Share	-88.98	-90.34	-67.48	-41.71	-58.97	-73.55	46.29	137.4	152.58	176.36	238.49	244.12	457.42	454.87
Tangible Book Value per Share	24.68	20.66	118.44	158.88	138.03	122.12	171.02	81.49	153.43	150.49	257.82	228.22	316.24	305.28
Basic Weighted Avg Shares	27	30	31	34	34	34	38	41	42	43	47	47	48	49
Sales/Revenue/Turnover	90	162	184	475	1,017	1,307	2,648	5,019	7,446	9,774	12,690	17,419	26,011	23,648
Operating Margin (%)	-506.24	-286.87	-427.64	-79.81	-62.28	-21.15	5.82	11.33	17.49	19.13	12.8	7.91	50.4	39.73
Depreciation Expense	98	99	36	33	61	66	90	154	237	330	383	522	608	754
Net Income, GAAP	-435	-482	-731	-317	-623	-513	-175	-200	182	1,258	1,066	389	8,094	6,766
Effective Tax Rate (%)	- -	- -	- -	- -	- -	- -	79.43	47.31	47.4	24.36	95.01	213.07	24.65	34.95
Profit Margin (%)	-482.06	-297.79	-398.03	-66.83	-61.29	-39.26	-6.62	-3.99	2.44	12.87	8.4	2.23	31.12	28.61
Working Capital	744	680	3,188	4,823	3,399	2,921	5,064	4,994	7,025	6,421	15,644	13,644	22,714	19,931
LT Debt	249	261	35	269	469	488	479	1,520	1,157	227	281	158	1,750	1,657
Total Equity	1,162	1,031	3,973	5,798	5,128	4,533	13,482	10,008	13,096	12,769	19,266	19,811	36,053	39,564
Return on Invested Capital (%)	- -	- -	- -	- -	- -	- -	0.31	2.19	4.94	9.42	0.46	-7.34	31.13	16.46
Return on Capital (%)	- -	- -	- -	- -	- -	- -	-17.41	-6.91	-1.93	11.18	17.65	5.59	39.35	39.82
Return on Common Equity (%)	- -	- -	- -	- -	- -	- -	- -	-5.48	3.03	17.83	11.31	3.41	48.42	38.02

	Dec'23	Mar'24	Jun'24
Total Current Assets	30,907	31,980	30,848
Accounts Receivable, Net	3,973	4,490	5,178
Cash, Cash Equivalents & STI	23,210	23,523	21,246
Inventories	2,331	2,497	2,976
Total Current Liabilities	8,194	10,764	10,917
Payables & Accruals	- -	- -	- -
ST Debt	1,949	4,627	4,363
Deferred Revenue	- -	- -	- -

	Dec'23	Mar'24	Jun'24
ST Debt	1,949	4,627	4,363
LT Borrowings	1,600	1,500	1,400
LT Finance Leases	150	107	257
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	50	50	50
Market Capitalization	134,389	150,140	116,348

Year	Q1	Q2	Q3	Q4	FY
2022	3,933	4,221	4,606	4,658	17,419
2023	4,206	9,890	6,451	5,463	26,011
2024	5,949	5,785	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	7.4	6.86	8.42	- -	8.19
2023	-0.06	34.99	11.68	- -	169.5
2024	29.17	-22.49	- -	- -	- -

GNI Group Ltd.

Growth Rates

(avg. rate of change)

Company Description

Working Capital

Capital Structure

Growth Rates

(avg. rate of change)

Quarterly Dividends Per Share

Year

Quarterly Revenue

Year

Quarterly Earnings Per Share

Year